{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:27:35Z","timestamp":1793978855796,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173852"],"award-info":[{"award-number":["82173852"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119210","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:41:54Z","timestamp":1786376514000},"page":"119210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Bridging DNA damage and cGAS-STING activation: Platinum (IV) prodrugs as single-molecule chemo-immunotherapeutics"],"prefix":"10.1016","volume":"319","author":[{"given":"Junkang","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2026.119210_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7150\/jca.49944","article-title":"Clinical value of docetaxel plus cisplatin (TP) induction chemotherapy followed by TP concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma","volume":"12","author":"Tao","year":"2021","journal-title":"J. Cancer"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119210_bib2","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1021\/acs.jmedchem.1c01248","article-title":"II)-NHC complex induces ROS-ERS-Related DAMP balance to harness immunogenic cell death in hepatocellular carcinoma","volume":"65","author":"Bian","year":"2022","journal-title":"J. Med. Chem."},{"issue":"50","key":"10.1016\/j.ejmech.2026.119210_bib3","doi-asserted-by":"crossref","first-page":"18218","DOI":"10.1002\/anie.201910014","article-title":"Expanding the arsenal of PtIV anticancer agents: multi-action PtIV anticancer agents with bioactive ligands possessing a hydroxy functional group","volume":"58","author":"Yempala","year":"2019","journal-title":"Angewandte Chemie-International Edition"},{"issue":"4","key":"10.1016\/j.ejmech.2026.119210_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"21","key":"10.1016\/j.ejmech.2026.119210_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25215167","article-title":"Photoactivatable platinum-based anticancer drugs: mode of photoactivation and mechanism of action","volume":"25","author":"Dai","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119210_bib6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"47","key":"10.1016\/j.ejmech.2026.119210_bib7","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119210_bib8","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem. Rev."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119210_bib9","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1002\/anie.202011593","article-title":"An efficient conjugation approach for coupling drugs to native antibodies via the PtII linker Lx for improved manufacturability of antibody-drug conjugates","volume":"60","author":"Merkul","year":"2021","journal-title":"Angewandte Chemie-International Edition"},{"issue":"21","key":"10.1016\/j.ejmech.2026.119210_bib10","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence","volume":"20","author":"de Biasi","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119210_bib11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.bbrc.2019.11.107","article-title":"Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma","volume":"522","author":"Harabuchi","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119210_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119210_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119210_bib14","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1021\/acsomega.9b03381","article-title":"Oxaliplatin-based Platinum(IV) prodrug bearing toll-like receptor 7 agonist for enhanced immunochemotherapy","volume":"5","author":"Tang","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.119210_bib15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jconrel.2023.08.035","article-title":"Emerging platinum(IV) prodrug nanotherapeutics: a new epoch for platinum-based cancer therapy","volume":"361","author":"Zheng","year":"2023","journal-title":"J. Contr. Release"},{"issue":"6230","key":"10.1016\/j.ejmech.2026.119210_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"issue":"6230","key":"10.1016\/j.ejmech.2026.119210_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"6121","key":"10.1016\/j.ejmech.2026.119210_bib18","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119210_bib19","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni.3558","article-title":"Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing","volume":"17","author":"Chen","year":"2016","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119210_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201902599","article-title":"Regulation of cGAS-Mediated immune responses and immunotherapy","volume":"7","author":"Saeed","year":"2020","journal-title":"Adv. Sci."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119210_bib21","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/cac2.70067","article-title":"Breaking barriers: the cGAS-STING pathway as a novel frontier in cancer immunotherapy","volume":"45","author":"Yan","year":"2025","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119210_bib22","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-020-01247-w","article-title":"cGAS-STING pathway in cancer biotherapy","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119210_bib23","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119210_bib24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.molcel.2013.05.022","article-title":"Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING","volume":"51","author":"Zhang","year":"2013","journal-title":"Mol. Cell"},{"issue":"7748","key":"10.1016\/j.ejmech.2026.119210_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-019-1000-2","article-title":"Structural basis of STING binding with and phosphorylation by TBK1","volume":"567","author":"Zhang","year":"2019","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119210_bib26","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-025-02812-3","article-title":"Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies","volume":"42","author":"Yusoh","year":"2025","journal-title":"Med. Oncol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119210_bib27","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","article-title":"Platinum-based drugs: past, present and future","volume":"77","author":"Dilruba","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7736","key":"10.1016\/j.ejmech.2026.119210_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-018-0705-y","article-title":"Design of amidobenzimidazole STING receptor agonists with systemic activity","volume":"564","author":"Ramanjulu","year":"2018","journal-title":"Nature"},{"issue":"6506","key":"10.1016\/j.ejmech.2026.119210_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba6098","article-title":"An orally available non-nucleotide STING agonist with antitumor activity","volume":"369","author":"Pan","year":"2020","journal-title":"Science"},{"issue":"6506","key":"10.1016\/j.ejmech.2026.119210_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb4255","article-title":"Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic","volume":"369","author":"Chin","year":"2020","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119210_bib31","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/emboj.2013.86","article-title":"Species-specific detection of the antiviral small-molecule compound CMA by STING","volume":"32","author":"Cavlar","year":"2013","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119210_bib32","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/ja0432618","article-title":"Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance","volume":"127","author":"Ang","year":"2005","journal-title":"J. Am. Chem. Soc."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119210_bib33","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1021\/cr400460s","article-title":"Metallodrugs in medicinal inorganic chemistry","volume":"114","author":"Mjos","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119210_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2021.213991","article-title":"Recent advances in the synthesis, stability, and activation of platinum (IV) anticancer prodrugs","volume":"442","author":"Xu","year":"2021","journal-title":"Coord. Chem. Rev."},{"issue":"29","key":"10.1016\/j.ejmech.2026.119210_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202505567","article-title":"Pyroptosis-inducing Platinum(IV) prodrugs via GSDME pathway for chemoimmunotherapy and metastasis inhibition in triple-negative breast cancer","volume":"12","author":"Yang","year":"2025","journal-title":"Adv. Sci."},{"issue":"7454","key":"10.1016\/j.ejmech.2026.119210_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/nature12305","article-title":"Structural mechanism of cytosolic DNA sensing by cGAS","volume":"498","author":"Civril","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119210_bib37","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/jgh.16926","article-title":"Cisplatin promotes hepatotoxicity by cGAS-STING mediated innate immune response","volume":"40","author":"Tao","year":"2025","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119210_bib38","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2026.119210_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217432","article-title":"Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy","volume":"611","author":"Kong","year":"2025","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119210_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwae020","article-title":"Combining cisplatin and a STING agonist into one molecule for metalloimmunotherapy of cancer","volume":"11","author":"Zhang","year":"2024","journal-title":"Natl. Sci. Rev."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119210_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2018.11.047","article-title":"Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity","volume":"25","author":"Sivick","year":"2018","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119210_bib42","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1021\/acs.chemrev.8b00209","article-title":"Stimuli-responsive therapeutic metallodrugs","volume":"119","author":"Wang","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119210_bib43","first-page":"149","article-title":"Rational design of anticancer platinum(IV) prodrugs","volume":"vol. 75","author":"Zhang","year":"2020"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119210_bib44","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1039\/C8DT03923B","article-title":"Emerging platinum(IV) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment","volume":"48","author":"Wang","year":"2019","journal-title":"Dalton Trans."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119210_bib45","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1021\/acs.chemrev.8b00271","article-title":"Toward multi-targeted platinum and ruthenium Drugs-A new paradigm in cancer drug treatment regimens?","volume":"119","author":"Kenny","year":"2019","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119210_bib46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.chempr.2019.10.013","article-title":"Classification of metal-based drugs according to their mechanisms of action","volume":"6","author":"Boros","year":"2020","journal-title":"Chem"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:01:05Z","timestamp":1793977265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":46,"alternative-id":["S0223523426006550"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119210","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging DNA damage and cGAS-STING activation: Platinum (IV) prodrugs as single-molecule chemo-immunotherapeutics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119210"}}